Menu

Recent Interviews

Heye Daun, President and CEO, Osino Resources Corp.

Heye Daun
President and CEO | Osino Resources Corp.
Suite 810 – 789 West Pender Street, V6C 1H2 Vancouver (CAN)

jbecker@osinoresources.com

Interview Osino Resources: "The market has not yet realized how fast we are advancing Twin Hills."


Bradley Rourke, President, CEO and Director, Scottie Resources Corp.

Bradley Rourke
President, CEO and Director | Scottie Resources Corp.
905 - 1111 West Hastings Street, V6E 2J3 Vancouver (CAN)

info@scottieresources.com

+1 250-877-9902

Interview Scottie Resources: Exciting Story in the Golden Triangle


Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


28. April 2021 | 07:04 CET

CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!

  • Biotechnology
Photo credits: pixabay.com

The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.

time to read: 3 minutes by Stefan Feulner


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


PsyBio Therapeutics - In pole position

The topic of magic mushrooms is new only to the stock market. The history of "magic mushrooms" containing psychedelic substances goes back to the Aztec era. But it was not until the late 1950s that psilocybin and psilocin were isolated as the effective substances of the mushroom by the scientist Albert Hofmann, who also discovered LSD. The pharmaceutical Company Sandoz marketed synthetically produced psilocybin under the name Indocybin® for experimental and psychotherapeutic purposes. However, due to its abuse as a narcotic drug, LSD and other psychedelics were banned by the Reagan administration in the early 1970s.

In recent years, more studies have again been conducted to prove the positive therapeutic effects of drugs such as psilocybin, LSD and other hallucinogens to treat several otherwise untreatable mental disorders such as chronic depression, post-traumatic stress disorder and drug addiction. In this regard, PsyBio Therapeutics is one step ahead of the competition in bringing a revolutionary drug to market.

In collaboration with the University of Miami's Department of Psychology, the Canadians work with other related compounds, studying their interactions and researching substances that work even better than pure psilocybin. The successful partnership with Miami University, which has already yielded several patents, was expanded last week. The neuropsychiatric drug discovery platform will be expanded to expedite the submission for approval of an investigational new drug, IND, to the FDA.

Overall, the Canadians see themselves as having a significant advantage over other competitors in research and patent prosecution. The unique selling point that favors PsyBio Therapeutics is a process that can produce psilocybin using bacteria significantly cheaper, faster and more environmentally friendly than any other published method. The Canadians are already a big player in the mental health space and this is demonstrated by recently announced personnel appointments. Bob Oliver, who has more than 25 years of experience in the pharmaceutical industry and has held various senior positions at Otsuka, Wyeth and Johnson & Johnson, is joining the Company, as is Dr. Michael Spigarelli, who has been appointed Chief Medical Officer.

PsyBio currently has a market capitalization of EUR 14.98 million. The industry is going strong right now. Companies in the same segment already have unicorn status. With its strong patents and successful collaborations, PsyBio Therapeutics could become a significant player in the fight against depression in the long term.

Evotec - Cooperation expanded

Good news from Evotec. The collaboration with Bristol Myers Squibb, which started in 2018, has now been extended by the Americans via option. As a result, Evotec will receive a payment of an unknown amount through the early extension. The partnership is ongoing in the field of targeted protein degradation. In addition, the screening is to be expanded and with it, the drug pipeline resulting from the collaboration.

Evotec Chief Scientific Officer Cord Dohrmann said, "Targeted protein degradation is an emerging new therapeutic modality with high potential to reach not only already validated targets, but also traditionally hard-to-reach targets, through a novel mechanism of action. This will allow first-in-class disease-modifying therapeutics to be explored and developed."

CureVac - The profiteer from the chaos?

Missing vaccines in Germany, plus the confusion surrounding AstraZeneca's vaccine. Now comes the next bad news. Since last weekend, the vaccine from BioNTech has also come under criticism. The Israeli Ministry of Health is investigating heart muscle inflammation cases that could be linked to the vaccine administration. The preliminary research mentions "dozens of cases" in which myocarditis has occurred. Myocarditis is an inflammation of the heart muscle, which can have various causes. The disease occurred mainly after the second dose, according to the Israeli coordinator for pandemic control, Nachman Ash.

The second German vaccine manufacturer, CureVac, is taking a little longer with its research. Now, however, the Tübingen-based Company is in the home stretch. The trial with CureVac's Corona vaccine is nearing completion. Almost all of the 40,000 subjects have been vaccinated twice and the safety and tolerability data look very good, said study leader Peter Kremsner. He expects the vaccine to be licensed and vaccinated soon, he said. "It can happen very quickly now. It should work in June unless something else comes up." It could always happen that the EMA still demands improvements, he said. If there is a vaccine to be added to the portfolio, it's CureVac!


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

10. May 2021 | 09:14 CET | by Stefan Feulner

CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!

  • Biotechnology

The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.

Read

20. April 2021 | 06:50 CET | by Nico Popp

CureVac, BioNTech, PsyBio: Yesterday's game changers - and tomorrow's?

  • Biotechnology

Vaccines against the coronavirus are changing everything. People who sat anxiously at home just a few weeks ago now dare to socialize again after their injection. Even if contact restrictions still apply - the feeling of being alive is different after the vaccination. German vaccine manufacturers, in particular, have used innovative mRNA technology to create vaccines that are largely scandal-free - and offer good protection. In the slipstream, new, innovative companies are already preparing to bring the next game changers to market. For investors, this can be a rewarding environment.

Read

13. April 2021 | 09:06 CET | by Carsten Mainitz

InnoCan Pharma, Cardiol Therapeutics, BevCanna - Watch out: undiscovered cannabis price rockets!

  • Biotechnology

Whether French explorer Jacques Cartier, who first named the region around present-day Quebec "Canada" in 1535, was acting on a hunch, or simply "Frenching" the word "Kanata" from the language of the Saint Lawrence Iroquois, can unfortunately no longer be determined with certainty today. However, what is certain is that today's "Canada" is the current stronghold of medical "cannabis." Thanks to liberal laws, hemp startups are sprouting up worldwide, and even established companies want a piece of the pie. Here are three interesting candidates for the portfolio, with current news and powerful price potential!

Read